Watts R W, Veall N, Purkiss P
Clin Sci (Lond). 1984 May;66(5):591-7. doi: 10.1042/cs0660591.
We have measured the plasma oxalate concentration (POx), urinary oxalate excretion (UOx), oxalate equilibrium distribution volume (ODV), oxalate metabolic pool size [(ODV) X (POx)], total plasma oxalate clearance (PCOx), renal (or dialyser) oxalate clearance (RCOx), non-renal oxalate clearance (NRCOx) and the tissue oxalate accretion rate (TOA) = [(NRCOx) X (POx)] in three patients with severe renal failure due to primary hyperoxaluria who were being treated by peritoneal dialysis or haemodialysis, or by renal transplantation. The clearance (either GFR or dialyser) of [99mTc]diethylenetriaminepenta-acetate (DTPA) and the extracellular fluid volume (ECF) measured as [99mTc]DTPA distribution volume were also determined. Negligible amounts of 14C were found in faeces or as 14CO2 in expired air and hence (NRCOx) = (PCOx-RCOx). Haemodialysis removed oxalate more efficiently than peritoneal dialysis in the patient where a direct comparison was possible. Neither treatment could keep up with the TOA when performed for clinically acceptable times. The plasma oxalate concentrations calculated from 14C clearance through the dialyser and the chemically determined concentration of the oxalate in the dialysate were in the range 111-146 mumol/l. This is higher than in normals and in hyperoxaluric patients who are not in renal failure. Hence, although the ODV and ECF are similar to those of hyperoxaluric patients without renal failure and normal control subjects, the oxalate metabolic pool (ODV X POx) is grossly enlarged. In the patient treated by renal transplantation, the oxalate pool size diminished concurrently with the resumption of oxalate excretion but expanded again as renal function decreased due to oxalosis.(ABSTRACT TRUNCATED AT 250 WORDS)
我们测定了3例因原发性高草酸尿症导致严重肾衰竭且正在接受腹膜透析、血液透析或肾移植治疗的患者的血浆草酸盐浓度(POx)、尿草酸盐排泄量(UOx)、草酸盐平衡分布容积(ODV)、草酸盐代谢池大小[(ODV)×(POx)]、总血浆草酸盐清除率(PCOx)、肾脏(或透析器)草酸盐清除率(RCOx)、非肾脏草酸盐清除率(NRCOx)以及组织草酸盐积聚率(TOA)=[(NRCOx)×(POx)]。还测定了[99mTc]二乙三胺五乙酸(DTPA)的清除率(肾小球滤过率或透析器清除率)以及作为[99mTc]DTPA分布容积测得的细胞外液量(ECF)。在粪便中或呼出气体中作为14CO2发现的14C量可忽略不计,因此(NRCOx)=(PCOx - RCOx)。在可进行直接比较的患者中,血液透析比腹膜透析更有效地清除草酸盐。当进行临床可接受时间的治疗时,两种治疗都无法跟上TOA。通过透析器的14C清除率计算出的血浆草酸盐浓度以及透析液中草酸盐的化学测定浓度在111 - 146μmol/L范围内。这高于正常人和未发生肾衰竭的高草酸尿症患者。因此,尽管ODV和ECF与未发生肾衰竭的高草酸尿症患者及正常对照者相似,但草酸盐代谢池(ODV×POx)明显扩大。在接受肾移植治疗的患者中,草酸盐池大小随着草酸盐排泄的恢复而减小,但随着因草酸盐沉着症导致肾功能下降又再次扩大。(摘要截短至250字)